藥明康德2019年三季度收入和經調整淨利潤保持加速增長

▎藥明康德/報導

藥明康德2019年三季度收入和經調整淨利潤1做到加速增長

上海，2019年10月30日，為全球生物醫藥行業提供全方位、一體化新藥研發和生產服務的能力和技術平台公司——無錫藥明康德新藥開發股份有限公司（股份代碼：603259.SH/2359.HK）發布2019年第三季度報告。

本文件純屬簡報性質，並非意圖提供相關事項的完整表述。有關信息請以公司在上海證券交易所網站(www.sse.com.cn)、香港聯合交易所網站(www.hkexnews.hk)和公司指定信息披露媒體刊登的2019年度三季度報告及相關公告為準。請廣大投資者謹慎投資，注意投資風險。

本文所披露的財務數據均以國際財務報告準則（International Financial Reporting Standards，或「IFRSs」）進行編制，幣種為人民幣。

本公司第三季度財務數據未經審計。

2019年7-9月業績亮點

• 營業收入增長34.7%至33.84億元。收入增速較去年保持加速趨勢。公司各個業務板塊均保持強勁的發展勢頭。毛利增長31.5%至13.77億元。毛利率為40.7%。2息稅折舊及攤銷前利潤11.55億元，同比增長22.0%。經調整息稅折舊及攤銷前利潤11.07億元，同比增長51.6%。經調整Non-IFRS歸屬於上市公司股東的淨利潤增長50.2%至6.64億元。經調整Non-IFRS歸屬於上市公司股東的淨利潤增速較去年顯著加快。歸屬於上市公司股東的淨利潤7.08億元，同比增長7.9%。報告期內，公司所投資標的的公允價值變動收益0.10億元；去年同期做到公允價值變動收益2.37億元。

2019年1-9月業績亮點

• 營業收入增長34.1%至92.79億元。毛利增長30.6%至36.60億元。毛利率為39.5%。3息稅折舊及攤銷前利潤29.14億元，同比增長7.3%。經調整息稅折舊及攤銷前利潤30.06億元，同比增長41.0%。經調整Non-IFRS歸屬於上市公司股東的淨利潤增長38.0%至18.42億元。歸屬於上市公司股東的淨利潤17.65億元，同比下降8.5%。歸屬於上市公司股東的淨利潤同比下降主要是由於報告期內，公司所投資標的的公允價值變動損失0.45億元，而去年同期做到公允價值變動收益6.69億元。

管理層評論

藥明康德聯席首席執行官胡正國先生表示：「2019年前三季度，公司總體收入和經調整Non-IFRS淨利潤保持了加速增長的趨勢。一方面，公司持續拓展新客戶並提高原有客戶的滲透率；另一方面，公司加強上下遊服務部門之間的轉化，平台協同性進一步增強。報告期內，公司新增客戶超過900家、活躍客戶超過3,700家，各項業務均保持穩健發展。」

胡正國先生補充道：「前三季度，公司里程碑和銷售分成的收費模式項目，助力客戶完成16個研究性新藥的臨床試驗申報，並獲得20個項目的臨床試驗許可；截至2019年9月30日，公司累計為國內客戶完成71個研究性新藥的臨床試驗申報，並獲得54個項目的臨床試驗許可。截至2019年9月30日，公司小分子CDMO/CMO服務項目所涉新藥物分子超過900個，其中，處於III期臨床試驗階段的項目40個、已獲批上市的項目17個；公司細胞和基因治療CDMO平台為24個I期臨床試驗項目以及9個II/III期臨床試驗項目提供服務。2019年9月，公司完成了3億美元零息可轉換債券發行，將有效支持公司業務拓展，以及外延並購戰略。」

藥明康德董事長兼首席執行官李革博士總結道：「在業務保持加速發展的同時，公司持續建能力，擴規模，進一步完善賦能平台建設。這些投入將有助於保持和增強公司的核心競爭力，為未來的發展奠定堅實的基礎。藥明康德將堅定不移地為全球客戶賦能，助力他們推動更多新藥、好藥早日問世，早日做到‘讓天下沒有難做的藥，難治的病’的偉大願景，造福病患。」

關於藥明康德

藥明康德（股票代碼：603259.SH/2359.HK）為全球生物醫藥行業提供全方位、一體化的新藥研發和生產服務。通過賦能全球制藥、生物科技和醫療器械公司，藥明康德致力於推動新藥研發進程，為患者帶來突破性的診療方案。本著以研究為首任，以客戶為中心的宗旨，藥明康德通過高性價比和高效的研發服務，助力客戶提升研發效率，服務範圍涵蓋化學藥研發和生產、細胞及基因療法研發生產、醫療器械測試等領域。目前，藥明康德的賦能平台正承載著來自全球30多個國家的3,700多家合作夥伴的研發創新項目，致力於將更多新藥、好藥帶給全球病患，早日做到「讓天下沒有難做的藥，難治的病」的願景。更多信息，請訪問公司網站：www.wuxiapptec.com

前瞻性陳述

本新聞稿有若干前瞻性陳述，該等前瞻性陳述並非歷史事實，乃基於本公司的信念、管理層所作出的假設以及現時所掌握的資料而對未來事件做出的預測。盡管本公司相信所做的預測合理，但是基於未來事件固有的不確定性，前瞻性陳述最終或變得不正確。前瞻性陳述受到以下相關風險的影響，其中包括本公司所提供的服務的有效競爭力、能夠符合擴展服務的時間表、保障客戶知識產權的能力、中美貿易摩擦影響等。本新聞稿所載的前瞻性陳述中僅以截至有關陳述做出當日為準，除法律有所規定外，本公司概不承擔義務對該等前瞻性陳述更新。因此，閣下應注意，依賴任何前瞻性陳述涉及已知及未知的風險。本新聞稿載有的所有前瞻性陳述需參照本部分所列的提示聲明。

Non-IFRS和經調整Non-IFRS財務計量

為補充本公司按照國際財務報告準則呈列的簡明綜合財務報表，本公司提供Non-IFRS歸屬於上市公司股東的淨利潤（不包括股權激勵計劃開支、上市及可轉股債券發行相關費用、匯兌波動相關損益、並購所得無形資產攤銷）、經調整Non-IFRS歸屬於上市公司股東的淨利潤（進一步剔除已做到及未做到權益類投資收益、應占合營公司盈虧）、經調整Non-IFRS每股收益作為額外的財務指標。這些指標並非國際財務報告準則所規定或根據國際財務報告準則編制。本公司認為經調整之財務指標有助了解及評估業務表現及經營趨勢，並有利於管理層及投資者透過參考此等經調整之財務指標評估本公司的財務表現，消除本公司並不認為對本公司業務表現具指示性的若干不尋常或非經常性項目。該等非國際財務報告準則的財務指標並不意味著可以僅考慮非公認準則的財務指標，或認為其可替代遵照國際財務報告準則編制及表達的財務信息。閣下不應獨立看待以上經調整的財務指標，可能將其視為替代按照國際財務報告準則所準備的業績結果，可能將其視為可與其他公司報告或預測的業績相比。

1. 經調整淨利潤：經調整Non-IFRS歸屬於上市公司股東的淨利潤。

2. 在中國企業會計準則編制基礎下，毛利增長31.5%至13.80億元。毛利率為40.8%。

3. 在中國企業會計準則編制基礎下，毛利增長30.2%至36.66億元。毛利率為39.5%。

WuXi AppTec Reports Third-Quarter 2019 Results

(SHANGHAI, October 30, 2019) — WuXi AppTec Co., Ltd. (stock code:603259.SH/2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its financial results for the third quarter and nine months ended September 30, 2019 (「Reporting Period」).

This document serves purely as a summary and is not intended to provide a complete representation of the relevant matters. For further information, please refer to the 2019 third quarterly report and relevant announcements published on the websites of the Shanghai Stock Exchange (www.sse.com.cn) and the Stock Exchange of Hong Kong (www.hkexnews.hk), and the designated media for dissemination of the relevant information. Investors are advised to exercise caution and be aware of the investment risks in dealing in the shares of the Company.

All financials disclosed in this press release are prepared based on International Financial Reporting Standards (or 「IFRSs」).

The 2019 Third-Quarter Report of the Company has not been audited.

Third-Quarter 2019 Financial Highlights

• Accelerated revenue growth of 34.7% year-over-year to RMB 3,384 million, which was broad-based across all our business segments.Gross profit grew 31.5% year-over-year to RMB 1,377 million. Gross profit margin was 40.7%.1EBITDA grew 22.0% Year-Over-Year to RMB 1,155 million.Adjusted EBITDA grew 51.6% Year-Over-Year to RMB 1,107 million.Adjusted non-IFRS net profit attributable to owners of the Company grew 50.2% year-over-year to RMB 664 million.Net profit attributable to owners of the Company grew 7.9% year-over-year to RMB 708 million. Net profit growth rate was slower than revenue growth rate due to RMB 227 million decrease in fair value gain of our investment portfolio from RMB 237 million in the third quarter of 2018 to RMB 10 million in the same period this year.

Year-to-Date 2019 Financial Highlights

• Accelerated revenue growth of 34.1% year-over-year to RMB 9,279 million.Gross profit grew 30.6% year-over-year to RMB 3,660 million. Gross profit margin was 39.5%.2EBITDA grew 7.3% Year-Over-Year to RMB 2,914 million.Adjusted EBITDA grew 41.0% Year-Over-Year to RMB 3,006 million.Adjusted non-IFRS net profit attributable to owners of the Company grew 38.0% year-over-year to RMB 1,842 million.Net profit attributable to owners of the Company was lower 8.5% year-over-year to RMB 1,765 million, due to a RMB 45 million loss from changes in fair value of our investment portfolio for the first nine months of 2019, versus a RMB 669 million gain in the same period last year.

Management Comment

Mr. Edward Hu, Co-CEO of WuXi AppTec, said, 「Our growth continued to accelerate for the third quarter of 2019.In addition, we continue to focus on customer development and business conversion with a strategy of following the projects and following the molecules, leveraging synergies across all our business segments. For the nine months ended September 30, we have gained over 900 new customers and our number of active customers now exceed 3,700.」

Mr. Edward Hu further commented, 「During the Reporting Period, our success-based drug discovery unit filed INDs for 16 new-chemical-entities for domestic customers with the China National Medical Products Administration and obtained 20 CTAs.As of September 30, 2019, we have cumulatively submitted 71 new-chemical-entity IND filings with the NMPA for our customers and obtained 54 CTAs. As of September 30, 2019, our small molecule CDMO/CMO pipeline has grown to more than 900 active projects, including 40 projects in Phase III clinical trials and 17 in commercial manufacturing, and our cell and gene therapies CDMO business provided services for 33 clinical stage projects, including 24 projects in Phase I and 9 projects in Phase II/III. In September 2019, we also completed the issuance of USD 300 million zero-coupon convertible bonds, providing the Company with a strong balance sheet for investments, business expansion and potential M&A.」

Dr. Ge Li, Chairman and CEO of WuXi AppTec, stated, 「Our business model and the platform we have built continue to perform well. We continue to invest in new capabilities and capacities and believe these investments will allow the company to sustain our long term growth.We will continue to focus on enabling global partners and assisting them to bring the best medicines to patients in need, and to realize our vision that ‘every drug can be made and every disease can be treated’.」

About WuXi AppTec

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 3,700 collaborators from over 30 countries to improve the health of those in need – and torealize our visionthat “every drug can be made and every disease can be treated.” Please visit: http://www.wuxiapptec.com

Forward-Looking Statements

This press release may contain certain 「forward-looking statements」 which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, our ability to protect our clients’ intellectual property, and unforeseeable international tension. Our forward-looking statements in this press release speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section.

Use of Non-IFRS and Adjusted Non-IFRS Financial Measures

We provide non-IFRS net profit attributable to owners of the Company and earnings per share, which exclude share-based compensation expenses, listing expenses and convertible bonds issuance expenses, foreign exchange-related gains or losses and amortization of intangible assets acquired in business combinations. We further provide an adjusted non-IFRS net profit attributable to owners of the Company and earnings per share, which exclude realized and unrealized gains or losses from our venture investments and joint ventures. Neither is required by, or presented in accordance with IFRS. We believe that the adjusted financial measures used in this press release are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual and non-recurring items that we do not consider indicative of the performance of our core business. However, the presentation of these adjusted non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.

1. If prepared under Accounting Standard for Business Enterprises of PRC, the gross profit grew 31.5% year-over-year to RMB 1,380 million. Gross profit margin was 40.8%.

2. If prepared under Accounting Standard for Business Enterprises of PRC, the gross profit grew 30.2% year-over-year to RMB 3,666 million. Gross profit margin was 39.5%.